<SEC-DOCUMENT>0001062993-15-004767.txt : 20150824
<SEC-HEADER>0001062993-15-004767.hdr.sgml : 20150824
<ACCEPTANCE-DATETIME>20150824062052
ACCESSION NUMBER:		0001062993-15-004767
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150824
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150824
DATE AS OF CHANGE:		20150824

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXARIA CORP.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		151069944

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4
		BUSINESS PHONE:		604-602-1675

	MAIL ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "form8k.pdf">


<HTML>
<HEAD>
   <TITLE>Lexaria Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR><B>Washington, D.C.
20549 </B><BR></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report <BR>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 <BR></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left colSpan=2>Date of
      Report (date of earliest event reported): August 24, 2015 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="33%">&nbsp;
    </TD></TR>
  <TR vAlign=bottom>
    <TD align=center colSpan=3>&nbsp;<B><FONT size=5>LEXARIA CORP.&nbsp;
      </FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center colSpan=3>(Exact
      name of registrant as specified in its charter) <BR></TD></TR>
  <TR vAlign=top>
    <TD align=center>Nevada </TD>
    <TD align=center width="33%">000-52138 </TD>
    <TD align=center width="33%">20-2000871 </TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer Identification No.) </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center>incorporation)
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="33%">&nbsp;
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="33%">&nbsp;
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left colSpan=2><BR>#950
      &#150; 1130 West Pender Street, Vancouver, British Columbia, Canada V6E 4A4 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="33%">&nbsp;
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      colSpan=2><BR>Registrant's telephone number, including area code: (604)
      602-1675 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="33%">&nbsp;
    </TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      colSpan=3><BR>(Former name or former address, if changed since last
      report.) <BR></TD></TR></TABLE>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions: </P>
<P align=justify>[&nbsp;&nbsp; ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) </P>
<P align=justify>[&nbsp;&nbsp; ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12) </P>
<P align=justify>[&nbsp;&nbsp; ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) </P>
<P align=justify>[&nbsp;&nbsp; ] Pre-commencement communications pursuant to
Rule 13e-4(c) under Exchange Act (17 CFR 240.13e -4(c)) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>Item 7.01 Regulation FD Disclosure. </B></P>
<P align=justify>A copy of the news release announcing the Company&#146;s technology
achieves Cannabidiol absorption rate 499% greater than baseline in laboratory
testing filed as exhibit 99.1 to this current report and is hereby incorporated
by reference. </P>
<P align=justify><B>TEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Exhibit No.</B> </TD>
    <TD align=left width="92%"><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#EEEEEE" ><a href="exhibit99-1.htm">99.1</a> </TD>
    <TD align=left width="92%" bgcolor="#EEEEEE"><a href="exhibit99-1.htm">News Release dated August 24, 2015
    </a>
  </TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>


<!--$$/page=-->
<A name="page_3"></A>

<P align="center">
<B>SIGNATURES </B></P>
<P align="justify">
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </P>
<P align="justify">
Dated: August 24, 2015 </P>
<TABLE style="font-size:10pt;border-color:black;border-collapse:collapse;" cellpadding="0" cellspacing="0" width="100%" border="0"><TR valign="top">
	<TD align=left width="50%">
&nbsp;</TD>
	<TD align=left width="10%">
&nbsp;
	</TD>
	<TD colspan=2 align=left>
Lexaria Corp.
	</TD>
</TR>
<TR valign="top">
	<TD align=left width="50%">
&nbsp;</TD>
	<TD align=left width="10%">
(Signature)
	</TD>
	<TD align=left style="border-bottom: 1px solid #000000;">
By:
&ldquo;<I>/s/ Chris Bunka&rdquo;</I>
	</TD>
	<TD align=right style="border-bottom: 1px solid #000000;">
<p align="left">&nbsp;</TD>
</TR>
<TR valign="top">
	<TD align=left width="50%">
&nbsp;</TD>
	<TD align=left width="10%">
&nbsp;
	</TD>
	<TD colspan=2 align=left>
Chris Bunka
	</TD>
</TR>
<TR valign="top">
	<TD align=left width="50%">
&nbsp;</TD>
	<TD align=left width="10%">
&nbsp;
	</TD>
	<TD colspan=2 align=left>
President &amp; CEO
	</TD>
</TR>
</TABLE>
<BR>

<HR noshade align="center" width="100%" size=5 color="black">


</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>



<HTML>
<HEAD>
   <TITLE> Lexaria Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>

</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">


<!--$$/page=-->
<A name="page_1"></A>

<P align="center" dir="rtl">
<B>Lexaria&rsquo;s Technology Achieves Cannabidiol Absorption Rate 499% Greater
<br>
Than Baseline in Laboratory Testing </B></P>
<P align="justify">
Kelowna, BC / August 24, 2015 / Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the &ldquo;Company&rdquo;) is very pleased to announce potential industry-changing achievements in enhanced gastrointestinal absorption of cannabidiol (CBD) utilizing
Lexaria&rsquo;s patent pending technology. The recent third-party testing was conducted in two phases of <I>in vitro</I> tests beginning in June and completed in August, 2015. </P>
<P align="justify">
The independent laboratory results have delivered average CBD permeability of 499% of baseline permeability, compared to CBD permeability without Lexaria&rsquo;s technology. These results exceed Company expectations. </P>
<P align="justify">
This was assessed in a strictly controlled, <I>in vitro </I>experiment using a human intestinal tissue model. Samples of Lexaria&rsquo;s commercially available CBD-fortified ViPova&trade; black tea were administered in the model compared with
concentration-matched CBD control preparations that lacked Lexaria&rsquo;s patent-pending formulation and process enhancements. Lexaria believes that its <I>in vitro</I> findings provide compelling evidence of the intestinal absorption enhancing
capabilities of its technology, based on which it is exploring opportunities to progress to more advanced, follow-on bioavailability testing in animals.</P>
<P align="justify">
The tests also showed 325% of baseline gastro-intestinal permeability of CBD comparing Lexaria&rsquo;s CBD-fortified ViPova&trade; black tea to a second control of CBD and black tea combined, <I>without</I> Lexaria&rsquo;s patent-pending formulation
enhancements. This confirms that the specialized processing undertaken by Lexaria during its manufacturing process together with its formulation enhancements, does indeed significantly improve absorption levels. </P>
<P align="justify">
As previously reported by the Company, bioavailability of CBD (or of THC) varies greatly by delivery method. Smoking typically delivers cannabinoids at an average bioavailability rate of 30% (Huestis (2007) Chem. Biodivers. 4:1770&ndash;1804;
McGilveray (2005) Pain Res. Manag. 10 Suppl. A:15A &ndash; 22A). By comparison, orally consumed cannabis edibles typically deliver cannabinoids at an average bioavailability rate of only 5% (Karschner et al. (2011) Clin. Chem. 57:66&ndash;75).</P>
<P align="justify">
The Company&rsquo;s present findings suggest that its technology may achieve a 5-fold improvement in cannabinoid absorption in edible form over that which can be achieved without its proprietary process and formulation enhancements. This
conceptually supports that Lexaria&rsquo;s technology represents a significant breakthrough in cannabinoid delivery by approximating the high absorption levels achieved as though through administration by smoking, but without the associated negative
effects on human health caused by smoking. </P>
<P align="justify">
&rdquo;I am very pleased with the performance of our patent-pending technology in this carefully designed and controlled experiment,&rdquo; said John Docherty, President. &ldquo;This evidences the
disruptive nature of Lexaria and its technology within the cannabinoid edibles
industry, and poises the Company to become a leader in the development of
potentially a wide range of product lines with enhanced gastro-intestinal
absorption performance capabilities.&#148; </P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">



<!--$$/page=-->
<A name="page_2"></A>

<P align="justify">
The tests were completed in two phases culminating with testing using simulated
intestinal fluid conditions that delivered these findings. These results were
stronger than earlier iterations of the tests that did not use a simulated
intestinal fluid environment and has contributed to Lexaria&rsquo;s understanding of the mechanisms at work. For these and other reasons, Lexaria believes that bioavailability testing in animals is likely to yield even stronger absorption
results in the presence of natural intestinal fluid conditions. </P>
<P align="justify">
CBD has been repeatedly found to provide beneficial pain relieving, anti-inflammatory, anti-anxiety, neuroprotection, anti-psychotic, and anti-convulsive effects among others. Lexaria&rsquo;s patent-pending technology could significantly reduce
individual serving requirements for CBD to consumers. This could lead to reduced costs of consumption for consumers and increased profitability for Lexaria. </P>
<P align="justify">
More detailed data from the results of the Lexaria experiments are available under strict confidentiality and non-compete agreements to potential industry partners who wish to license our proprietary technology to improve the bioavailability of key
ingredients within their products while simultaneously enhancing their firm&rsquo;s profitability.</P>
<P align="justify">
Lexaria also reminds stakeholders that the same technology used to enhance the absorption of CBD in the recent laboratory tests, is applicable to THC, nicotine, NSAIDs and other lipophilic compounds that are widely used today. </P>
<P align="justify">
&ldquo;We are thrilled to have generated these positive laboratory results substantiating the effectiveness of our technology,&rdquo; said Chris Bunka, CEO. &ldquo;We believe that this only increases the likelihood of our patents being granted in
due course since it demonstrates how our technology improves absorption of CBD. We have every reason to believe it will function in a similar manner if tested with THC, nicotine, or any of the other molecules named in our patent applications.&rdquo;

</P>
<P align="justify">
Lexaria is investigating the possibility to pursue publication of its findings in a reputable scientific journal.</P>
<P align="justify">
About Lexaria </P>
<P align="justify">
Lexaria is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies. Lexaria&rsquo;s technology enables higher bioavailability rates for CBD; THC; NSAIDs;
Nicotine and other molecules than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria hopes to reduce
other common but less healthy ingestion methods such as smoking as it embraces the benefits of public health. www.lexariaenergy.com About ViPova<SUP>TM</SUP> </P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">



<!--$$/page=-->
<A name="page_3"></A>

<P align="justify">
ViPova<SUP>TM</SUP> uses only legal hemp oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPova<SUP>TM</SUP>-branded tea. ViPova<SUP>TM</SUP> uses its patent-pending process to infuse concentrated amounts of
hemp oil within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova<SUP>TM</SUP> has this ground-breaking technology for hemp oil/lipid infusion. www.vipova.com </P>
<P align="justify">
FOR FURTHER INFORMATION
PLEASE CONTACT:</P>
<P align="justify">
Lexaria Corp.<BR>
Chris Bunka<BR>
Chairman &amp; CEO<BR>
(250) 765-6424 <BR>
</P>
<P align="justify">
FORWARD-LOOKING STATEMENTS </P>
<P align="justify">
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations,
cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: the potential industry-changing achievement as a results of the
laboratory test findings, that the <I>in vitro</I> findings provide compelling evidence of the future intestinal absorption enhancing capabilities of the technology, that the Company may become a leader in the development of potentially a wide range
of product lines with enhanced gastro-intestinal absorption performance capabilities, that bioavailability testing in animals is likely to yield even stronger absorption results in the presence of natural intestinal fluid conditions, or that the
technology will function in a similar manner if tested with THC, nicotine, or any of the other molecules named in our patent applications. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current
information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and
maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no
assurance that the medical marijuana, hemp oil sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing
capital is sufficient for the Company's needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful.
There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that additional testing will continue to result in any improvement in
absorption versus controls. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. There is no assurance that any patent application in the USA or any other nation
or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexaria&rsquo;s postulated uses, benefits, or
advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova<SUP>TM</SUP> products are not intended to diagnose, treat,
cure or prevent any disease.</P>

<P align="justify">
<I>The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. </I></P>

<HR noshade align="center" width="100%" size=5 color="black">


</BODY>

</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
